Compare F5 Inc (FFIV) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Smith & Nephew plc — how do they compare? F5 Inc trades at $480.49 (market cap $26.14B), while Smith & Nephew plc trades at $27.14 (market cap $11.10B). The key difference: F5 Inc is far larger — about 2.4× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while F5 Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and Smith & Nephew plc for 120 Days on average.
| FFIV | SNN | |
|---|---|---|
Market Cap | $26.14B | $11.10B |
Volume | 503,146 | 1,051,703 |
Sector | Technology | Health |
52-Week High | $469.79 | $37.17 |
52-Week Low | $223.99 | $26.42 |
Typical Hold Time | 38 Days | 120 Days |
Enterprise Value | $24.78B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $479.27, up 2.7% on the day and near its 52-week high, with a bullish technical trend and strong support at $457. The company reported robust earnings, beating estimates for three consecutive quarters, with Q3 2026 EPS expected at $4.26. Revenue growth accelerated to $3.09B in 2025, and net income margin improved to 22.42%. Recent news highlights F5's leadership in WAAP platforms and AI security innovations, reinforcing its competitive edge.
The outlook for FFIV is positive, driven by earnings momentum and strategic positioning in AI security. However, the stock's elevated valuation multiples (P/E of 36.78) pose a risk if growth slows. Analyst consensus is mixed with a $416.60 price target below the current price, suggesting caution despite bullish technicals. Key risks include competitive pressures and execution challenges in integrating new technologies.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
